- Home
- PZZA vs ARVN Comparison
PZZA vs ARVN Comparison
Compare PZZA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PZZA
- ARVN
- Stock Information
- Founded
- PZZA 1984
- ARVN 2015
- Country
- PZZA United States
- ARVN United States
- Employees
- PZZA N/A
- ARVN N/A
- Industry
- PZZA Restaurants
- ARVN Biotechnology: Pharmaceutical Preparations
- Sector
- PZZA Consumer Discretionary
- ARVN Health Care
- Exchange
- PZZA Nasdaq
- ARVN Nasdaq
- Market Cap
- PZZA 1.5B
- ARVN 1.2B
- IPO Year
- PZZA 1993
- ARVN 2018
- Fundamental
- Price
- PZZA $41.01
- ARVN $6.90
- Analyst Decision
- PZZA Buy
- ARVN Buy
- Analyst Count
- PZZA 12
- ARVN 13
- Target Price
- PZZA $55.55
- ARVN $34.42
- AVG Volume (30 Days)
- PZZA 1.1M
- ARVN 3.6M
- Earning Date
- PZZA 05-08-2025
- ARVN 05-06-2025
- Dividend Yield
- PZZA 4.49%
- ARVN N/A
- EPS Growth
- PZZA 2.42
- ARVN N/A
- EPS
- PZZA 2.54
- ARVN N/A
- Revenue
- PZZA $2,059,387,000.00
- ARVN $263,399,999.00
- Revenue This Year
- PZZA $3.43
- ARVN N/A
- Revenue Next Year
- PZZA $3.43
- ARVN $7.99
- P/E Ratio
- PZZA $16.15
- ARVN N/A
- Revenue Growth
- PZZA N/A
- ARVN 235.54
- 52 Week Low
- PZZA $35.28
- ARVN $6.75
- 52 Week High
- PZZA $66.42
- ARVN $39.40
- Technical
- Relative Strength Index (RSI)
- PZZA 42.20
- ARVN 24.13
- Support Level
- PZZA $39.28
- ARVN $8.51
- Resistance Level
- PZZA $42.21
- ARVN $7.36
- Average True Range (ATR)
- PZZA 1.83
- ARVN 0.45
- MACD
- PZZA -0.36
- ARVN 0.08
- Stochastic Oscillator
- PZZA 21.82
- ARVN 6.20
About PZZA Papa John's International Inc.
Papa John's is one of the largest players in the global QSR, or quick-service restaurant, pizza market, boasting more than 6,000 restaurants across nearly 50 countries at the end of 2024. The firm operates a predominantly franchised system, owning 9% of its restaurants and generating revenue from franchise royalties, sales of pizza and related products at its company-owned stores, and sales from its commissary supply chain. The firm is the fourth-largest limited-service pizza chain globally and third in the US (Euromonitor International), with a sizable presence in the UK, China, South Korea, and Chile.
About ARVN Arvinas Inc.
Arvinas Inc is a United States-based biopharmaceutical company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins.. The company's proprietary Proteolysis-Targeting Chimera (PROTAC), work by inducing the cell's own ubiquitin-proteasome system to target, degrade and remove disease-causing proteins. The group's product candidates are bavdegalutamide, ARV-471 and ARV-766.